клеточные, макрофагальные и В-клеточные иммунные реакции, в том числе ингибирует Т-клеточную активацию и пролиферацию, уменьшает количество "double negative" Т-клеток, восстанавливает синтез ИЛ-2, ингибирует синтез IgG В-лимфоцитами и продукцию ИЛ-1. Недавно было показано, что рапамацин подавляет активацию преимущественно Тh2-клеток (N. Ferraresso и соавт., 1994).

Эти данные свидетельствуют о целесообразности испытания препарата при лечении аутоиммунных ревматических заболеваний.

Список литературы к главе "Циклоспорин А, FК-506, рапамицин"

1.Усова С. Б.: Циклоспорин А в терапии ревматоидного артрита. Клиническая ревматология, 1993; No. 1: 44-48.

2.Aldo V., Londino Ir., Santoro D., et al.: FK 506 in the treatment of psoriasis and psoriatic arthritis. Arthritis Rheum., 1994; 37 (Suppl.): S207.

3.Anderson J., Nagy S., Groth C.-G. et al.: Effect of FK506 and cyclosporine A on cytokine production studied in vitro at a single-cell level. Immunology 1992; 75: 136-142.

4.Appelboom Т., Itzkowitch D.: Cyclosporine in succesful control of rapidly progresstve scle-roderma. Am. J. Med. 1987: 82: 866-867.

5.Arita С., Hotokebuchi Т., Miyahara H., et al.: Inhibition by FK506 of established colla-gen-induced arthritis in rats. Clin. Exp. Immunopathol. 1990; 82: 456-461.

6.Baeder W. L, Sredy J., Sehgal S. N. et al.: Rapamycin prevens the onset of insulin-dependent diabetes mellitus (IDDM) In NOD mice. Clin. Exp. Immunol. 1992; 89: 174-178.

7.Brahn E., Peacock D. J., Banquerico M. L.: Supression of collagen-induced arthritis by combination cyclosporin A and methotrexate therapy. Arthritis Rheum. 1981; 34: 1282-1288.

8.Baumbauer R., Schiel R., Keller H. E.: Cyclosporin A in systemic lupus erythematosus. Lupus 1992; 1: 169 (abst).

9.Bensen W., Tugwell P., Roberts R., et al.: Combination therapy of cyclosporin with methotrexate and gold in rheumatoid arthritis (2 pilot study). Arthritis Rheum. 1994; 37 (suppl.): S-335.

10.Binder A. I., Grahem E. M., Sanders M. D., et. al.: Cyclosporin A in the treatment of severe Behcet's uveitis. Br. J. Rheumatol. 1987; 26: 285-291.

11.Blank M., Ben-Bassat M., Shoenfeld Y.: The effect of cyclosporin on early and late stages of experimental lupus. Arthritis Rheum. 1992; 35: 1350-1355.

12.Brier B. E., Mattila P., Standaert R. F. et al.: Two distinct signal transmission pathways in T-lymphocytes are inhibited by complex formed between an immunophilin and either FK-506 or rapamycin. Proc. Natl. Acad. Sci USA., 1990: 87: 9231-9235.

13.Camps J., Sangro B., Garcia N. et al.: Felty's syndrome: response to cyclosporin A with disappearence of neutrophil auto-antibodies (letter). Arthritis Rheum. 1991; 34; 253-255.

14.Cherin P., Crevon M.-C., Hauw J.-J., et. al. Mechanisms of lysis by cytotoxic cells in inflammatory myopathies: a study of perforin and serine esterase gene expression by in situ hybridisation and protein TIA-I expression by immunohistochemistry, from muscular biopsies. Arthritis Rheum. 1993; 36 (suppl.): S84.

15.Chrieber S. L.: Chemistry and biology of the immunophillins and their immunosupressive ligands. Science 1991; 251: 283-287.

16.Claw D. J., Alloway J. A., Read C., et. al.: The use of cyclosporin in the eosinophillia myalgia syndrome (EMS). Arthritis Rheum. 1991; 34 (suppl): R29.

17.Clements P. J., Lachenbruch P. A., Sters M., et. al.: Cyclosporine in systemic sclerosis. Arthritis Rheum. 1993; 36: 75-83.

18.Curkey R. K., MacFarlane A. W., Vickers C. F. H.; Pyoderma gangrenosa treated with cyclosporin A. Br. J. Dermatol. 1985; 113: 601-604.

19.Dammacco F., Riza R., Ferraccioli G. F., et al.: Efficacy and tolerability of cyclosporin A in association with corticosteroids vs corticosteroids alone in systemic lupus erythematosus. Arthritis Rheum. 1994: 37 (suppl.): S-407.

20.Danko K., Szegedi G. : Cyclosporin A treatment of dermatomyositis. Arthritis Rheum. 1991; 34: 933-934.

21.Dougados M., Torley H.: Efficacy of cyclosporin in rheumatoid arthritis; woldwide experience. Brit. J. Rheumatol. 1993; 32 (Suppl. 1): 57-59.

22.Drosos A. A., Scopouli F. N., Costopoulos J. S., et. al.: Cyclosporin A (CyA) in primary Sjogren's syndrome: a double blind study Ann. Rheum. Dis. 1986; 45: 732-735.

23.Elgart G., Stover P., Larson K. et al.: Treatment of pyoderma gangrenosum with cyclosporin: result in seven patients. J. Amer. Acad. Derm. 1991; 24: 83-86.

24.Favre H., Miesher P. A., Huang Y. P., et. al.: Cyclosporin in the treatment in the lupus nephritis. Amer. J. Nephrol 1989; 9: 57-60.

25.Feutren D., Querin S., Noel L. H., et al. Effects of cyclosporin in severe systemic lupus erythematosus. J. Pediatr., 1987; III: 1063-1068.

26.Ferraresso N., Tian L., Ghobrial R. et al.: Rapamicine Inhibits production of cytotoxic but not noncytotoxic

antibodies and preferentially activate Th2 cell that inducible long-term survival of heart allograft reaction. J. Immunol. 1994; 153: 3307-3318.

27.Frances C., Brauchet M. C., Bletry 0. et. al.: Skin collagen from scleroderma patients before and after cyclosporin treatment Clin. exp. dermatol. 1988; 13: 1-3.

28.Ficher G. Wittmann L. B., Lang K. et. al. Cyclophilin and peptidyl-propyl cis-trans isomerase are probably identical proteins. Nature, 1989; 337: 467-478.

29.Gisslinger H., Burghuber O. C., Stacher G., et. al.: Efficacy of cyclosporin A in systemic sclerosis. Clin. exp. rheumatol. 1991; 1991; 9: 303-309.

30.Henderson В., Staines N. A., Burrai 1., Сох J. H.: The anti-arthritis and immunosuppres-sive effects of cyclosporin on arthritis induced in the rat by type II collagen. Clin. Exp. Immunol. 1984; 57: 51-56.

31.Henderson D. J., Naya I., Bundick R. V., et al.: Comparison of the effects of FK-506, cyclosporin A and rapamycin on IL-2 production. Immunol. 1991; 73: 316-323.

32.Hughes J. R., Smith E., Higgins E. M. et al.: Pyoderma ganrenosum in a patient with rheumatoid arthritis responding to treatment with cyclosporin A, Brit. J. Rheumatol. 1994; 33: 680-681.

33.Hussen M. M., Mooij J. M. V., Roujouleh H.: Cyclosporine in the treatment of lupus nephritis including two patients treated during pregnancy. Clin. Nephrol, 1993; 40: 160-163.

34.Israel-Biet D. I., Noel L. H., Bach M. A.: Marked reduction of DNA antibodies production and glomerulopathy in thymulin (FTS-Zn) or cyclosporin-A treated (NZBxNZW)FI mice. Clin. exp. immunol. 1983; 54: 359-365.

35.Inamura N., Hashomoto M., Nakahara K., et al.: Immunosupressive effect of FK-506 on collagen-induced arthritis in rats. Clin. Innunol. Immunopathol. 1988; 46: 82-90.

36.Jones M. G., Harris G.: Prolongation of life in female NZB/NZW (Fl) mice by cyclosporin A. Clin. exp. immunol, 1985; 59: 1-9.

37.Kahan В. D., Chang J. Y., Sehgal S. N.: Preclinical evaluation of a new potent immuno-suppressive agent, rapamycin. Transplantation 1991; 52: 185-191.

38.Kahan B. D.: Cyclosporin. New Engl. J. Med. 1989; 321: 1725-1738.

39.Keicho N., Sawada S., Kitamura K. et al.: Effects of immunosuppressant, FK506, on inter-leukin I alpha production by human macrophages and a macrophage-like cell line, U973. Cell. Immunol 1991; 132: 285294.

40.Kuo C. J., Chung J., Fiorentino D. V. et al.: Rapamycine selectively inhibits interleukin 2 activatioin of p70S6 kinase. J. Exp. Med. 1992; 358: 70-79.

41.Kurki P. Т.: Safety aspects of the long term cyclosporin A therapy. Scand. J. Rheumatol. 1992; 21 (Suppl. 95): 35-38.

42.Landewe R. B. M., Miltenburg A. M. M., Breedveld F. C. et al.: Cyclosporine and chloroquine synergistically inhibit the interferon gamma production by CD4 positive and CD8 positive T-cell clones derived from a patient with rheumatoid arthritis. J. Rheumatol., 1992; 19: 1353-1357.

43.Landewe R. B. M., Coel T. H. S., Rijthoven A. W. A. M. et al.: A randomized, double-blind, 24-week controlled study of low-dose cyclosporine versus chloroquine for early rheumatoid arthritis. Arthritis Rheum., 1994; 37: 637-643.

44.Landewe R. B. M., Dijkmans B. A. C., van der Woude F. J., et al.: Long-term low-dose cyclosporin in patients with rheumatoid arthritis. Arthritis Rheum, 1994; 37 (suppl.): S-361.

45.Leuenberger P. M., Miescher P. A.: Sjogren's syndrome: treatment with cyclosporin A (CsA). J. Autoimmun. 1992; 5: A51.

46.Macleod A. M. Thompson A. W. FK-506: an immunosupressant for the 19890s? Lancet 1991; 337: 25-27.

47.Magid M. L., Gold M. H.: Treatment of recalcitrant pyoderma gangrenosa with cyclosporin. J. Amer Acad. Dermatol. 1989; 20: 293-294.

48.Martel R. R., Klicius J., Galet S.: Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can. J. Physiol. Pharmacol. 1977; 55: 48-51.

49.Masuda К., Urayma A., Kogune M.: Double-masked trial of cyclosporin versus colchicin and long-term open study of cyclosporin in Bechcet's disease. . Lancet, 1989; 1: 1093-1095.

50.Morice W. G., Brunn G. J., Wiederrechts G., et al.: Rapamycine-induced inhibition of p34cdc2 kinase activation is associated with g l/S-phase growth arrest in T lym-phocytes. Biol. Chem. 1993; 268: 37.

51.Mountz J. D., Smith H. R., Wilder J., Reeves P., Steinberg A. D.: CS-A therapy in MRL-lpr/lpr mice: amelioration of immunopathology despite autoantibody production. J. Immunol. 1987: 138: 157-163.

52.Oddis C. V., Caroll P., Abu-Elmagd K., et al.: FK 506 in the treatment of polimiositis. Arthritis Rheum., 1994 (Suppl.); 37: R19.

53.Panayi G. S., Tugwell P.: The use of cyclosporin A in rheumatoid arthritis: conclusions of an international review. Brit. J. Rheumatol., 1994; 33: 967-969.

54.Priori R., Paroli M. P., Luan F. L., et al.: Cyolosporin A in the treatment of relapsing poly-chondritis with severe reccurent eye involvment. Brit. J. Rheumatol. 1993; 32: 352.

55.Russel M. L., Schachter R. K.: Cyclosporin treatment of systemic sclerosis. Arthritis Rheum. 1988; 31 (suppl. 4): S51.

56.Saadeh O. K., Bridges W., Burwick F. et. al.: Induction of remission of dermatomiositis (DM) in an adult